Selank clears a bar that almost nothing else in the “research peptide” category clears: it has an actual published human trial with rating-scale data attached to it. That alone puts it ahead of most of what gets sold alongside it online. The problem is how low that bar turns out to be once you read the trial itself. One study, 62 patients, a single Russian research group, an active-comparator design with no placebo arm, and a design that the published record does not describe as randomized.[1] Selank having a human trial is real. Selank having the kind of evidence base its marketing implies is not.
What the one human trial found
The trial, published in 2008 by Zozulia and colleagues in a Russian neurology and psychiatry journal, studied 62 patients with generalized anxiety disorder (GAD) and neurasthenia.[1] Thirty received selank. Thirty-two received medazepam, an older benzodiazepine.
62 patients in the only human trial identified for selank PMID 18454096
The researchers tracked outcomes with three standard instruments: the Hamilton scale, the Zung scale, and the Clinical Global Impression (CGI) scale. The anxiolytic effects of the two drugs came out similar. Selank’s authors also reported an antiasthenic and psychostimulant effect that medazepam did not produce, and the study tied clinical improvement to a biological marker, the half-life of leu-enkephalin in blood serum, which lengthened during selank treatment and correlated with symptom improvement.
That is a real result. It is also the entire published human efficacy record for this peptide, as far as the searches behind this article could establish.
The comparator problem
A trial that compares a new drug to an existing one, rather than to placebo, answers a narrower question than most readers assume. It can show selank performs about as well as medazepam. It cannot rule out that both drugs would have looked similar against an inert control, because no inert control was run.
Whether the 2008 trial randomized patients to the two arms is not stated in what’s available from the published abstract. Two things worth knowing before treating this as settled: it was not placebo-controlled, and its randomization procedure isn’t documented in the source record. For a deeper walk through that specific design gap, see Selank’s only randomized trial compared it to a drug, not a placebo.
Bottom line: Selank clears a bar most peptides sold alongside it never approach, one published human trial with real rating-scale data. That trial has no placebo arm, does not document its randomization procedure, and has never been repeated outside a single Russian research group.
The mechanism: one human finding, the rest is rodent
Selank is a synthetic analog of the endogenous peptide tuftsin.[2] Its best-documented mechanism, and the only one with human data behind it, is enzyme inhibition. In patients with anxiety and phobic disorders, researchers found a shortened half-life of leu-enkephalin and reduced enkephalinase activity in the blood during generalized anxiety; patients with panic disorder and agoraphobia did not show the same pattern. Selank dose-dependently inhibited that enzymatic breakdown of plasma enkephalin, with an IC50 of 15 micromolar, outperforming the peptidase inhibitors bacitracin and puromycin in the same assay.[3]
15 μM IC50 at which selank inhibited enkephalin-degrading enzymes in patient blood PMID 11550013
The logic mirrors a mechanism most readers already know from diabetes care. DPP-4 inhibitors do not add more GLP-1 to the body. They block the enzyme that breaks GLP-1 down, so the hormone the body already makes lingers longer. Selank’s proposed anxiolytic effect runs on the same principle, aimed at enkephalins, the body’s own opioid-like peptides, instead of GLP-1.
Everything past that single human enzyme study is animal work. In rats exposed to hypoxia during gestation, selank increased sensory attention two to three fold, improved learning by half again as much, and restored the balance of serotonin and noradrenaline in the brain.[2] In rats given chronic ethanol for 30 weeks, selank prevented the ethanol-induced rise in brain-derived neurotrophic factor in the hippocampus and prefrontal cortex, and protected against the memory and attention problems that came with it.[4] That BDNF effect has been shown in ethanol-exposed rats. It has not been shown in humans, with or without alcohol exposure.
Human evidence: one blood-enzyme study tying enkephalinase inhibition to symptom improvement.
Animal evidence: hypoxia recovery, ethanol-related memory protection, and behavioral effects in rat and mouse models of stress and depression.
Most of what gets said about selank’s mechanism was measured in a rodent brain. Only the enzyme finding above came from a person.
What’s documented and what isn’t
Selank: what's documented, what isn't
Claim | Status | Basis |
|---|---|---|
Human anxiety trial exists | Documented | 62-patient active-comparator study, Zozulia et al. 2008 |
Placebo-controlled design | Not documented | Active comparator (medazepam) only |
Randomized design | Not documented | Not stated in the published abstract |
Administration route in the human trial | Not documented | Route not specified in the available record |
Trials replicated outside Russia | None found | No Western trial record located |
Phase 3 clinical testing completed | Reported | Referenced as background in a 2008 rodent behavior paper |
Long-term safety data | Absent | No trial identified tests dosing beyond weeks |
Based on the trial and review record surfaced for this article.
The phase 3 line is worth sitting with. A 2008 paper studying selank’s effects on depressive behavior in rats and mice describes selank, in passing, as “a working element of a new peptide drug having completed the third phase of the clinical testing as a selective anxiolytic.”[5] That is a real, citable claim about the drug’s regulatory history in Russia. It is not the same as FDA approval, and it does not mean the compound sold as “selank” on a US supplement site went through any of that testing, or that it is regulated anywhere it’s currently purchased.
The supplement gap
A 2021 clinical pharmacology review put selank in blunt company. Alongside phenibut, another Russian GABAergic drug, selank was described as “poorly studied” and flagged as a substance “inexplicably sold to US consumers as dietary supplements.”[6] The same review noted that poison control centers have logged a rising number of calls tied to phenibut specifically, and called for real evaluation of abuse potential before these compounds reach the public.
The supplement gap: a 2021 pharmacology review lumped selank with phenibut as a poorly studied Russian drug reaching US consumers faster than any abuse-potential testing has caught up with it.[6]
Nothing in the record surfaced for this article establishes what selank’s adverse-event profile looks like at the doses people take, how it interacts with SSRIs, benzodiazepines, or other peptides users commonly stack it with, or what happens with use beyond a few weeks. For a closer look at that gap specifically, see Selank’s side effects are barely documented in humans.
Semax and the same problem, twice
Selank gets sold constantly alongside semax, another Russian-developed peptide from the same research tradition, usually marketed for cognition rather than anxiety. This article’s searches could not turn up a citable comparison of semax’s human trial record against selank’s, so that comparison is left out rather than asserted. What can be said honestly is that the two compounds share a structural problem: a research history built almost entirely inside one country’s psychiatric research establishment, with essentially no independent replication elsewhere. Semax vs Selank: two Russian peptides, one shared evidence problem goes further into that comparison.
The honest version of the claim
Selank is not nothing. A blood-enzyme mechanism tied to a real clinical population, a 62-patient trial against an actual anxiolytic rather than nothing, and a reported phase 3 completion in its home country put it ahead of most compounds that show up in the same online stores.
Clearing a low bar does not make a compound clinically established, and what’s still missing is substantial:
No placebo arm in the one trial that exists.
No documented randomization procedure.
No replication outside one country’s research pipeline.
No systematic human safety data at the doses people use.
Selank earns the modest credit that one real trial buys. Its sellers are currently claiming quite a bit more than that.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
[Selank-induced normalizing effects on the integrative brain activity and biogenic amine level disorders due to antenatal hypoxia].. Rossiiskii fiziologicheskii zhurnal imeni I.M. Sechenova, 2006.
The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity.. Bulletin of experimental biology and medicine, 2001.
Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats.. Bulletin of experimental biology and medicine, 2019.
[Effects of heptapeptide selank on genetically-based and situation-provoked symptoms of depression in behavior in WAG/Rij and Wistar rats, and in BALB/c mice].. Zhurnal vysshei nervnoi deiatelnosti imeni I P Pavlova, 2008.
Sedative-Hypnotic Agents That Impact Gamma-Aminobutyric Acid Receptors: Focus on Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, and Selank.. Journal of clinical pharmacology, 2021.
